Search research articles
Contact Us
Filters
Showing results (61-70 of 107) with videos related to
Page
of 11
Sort By:
Oncotarget
|
October 15, 2017
Melflufen - a peptidase-potentiated alkylating agent in clinical trials
Malin Wickström, Peter Nygren, Rolf Larsson, et al.
Cancer Chemotherapy and Pharmacology
|
April 17, 2013
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias
Robert O'Connor, Melissa G Ooi, Justine Meiller, et al.
Blood
|
March 14, 2019
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Joseph Mikhael, Paul Richardson, Saad Z Usmani, et al.
American Journal of Hematology
|
May 15, 2024
Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma
Shaji Kumar, S Vincent Rajkumar, Dragan Jevremovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2007
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
Robert A Kyle, Gary C Yee, Mark R Somerfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2018
Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update
Kenneth Anderson, Nofisat Ismaila, Patrick J Flynn, et al.
Cancer Medicine
|
October 13, 2020
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients
Andrew Belch, Nizar Bahlis, Darrell White, et al.
Leukemia & Lymphoma
|
February 26, 2008
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
Paul Richardson, Constantine Mitsiades, Kathleen Colson, et al.
Seminars in Oncology
|
April 30, 2003
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
Morie A Gertz, Athanasios Anagnostopoulos, Kenneth Anderson, et al.
Molecular Pharmacology
|
April 6, 2022
Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake
Vusumuzi N Hove, Kenneth Anderson, Elizabeth R Hayden, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 107) with videos related to
Sort By:
Page
of 11
Oncotarget
|
October 15, 2017
Melflufen - a peptidase-potentiated alkylating agent in clinical trials
Malin Wickström, Peter Nygren, Rolf Larsson, et al.
Cancer Chemotherapy and Pharmacology
|
April 17, 2013
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias
Robert O'Connor, Melissa G Ooi, Justine Meiller, et al.
Blood
|
March 14, 2019
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Joseph Mikhael, Paul Richardson, Saad Z Usmani, et al.
American Journal of Hematology
|
May 15, 2024
Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma
Shaji Kumar, S Vincent Rajkumar, Dragan Jevremovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2007
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
Robert A Kyle, Gary C Yee, Mark R Somerfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2018
Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update
Kenneth Anderson, Nofisat Ismaila, Patrick J Flynn, et al.
Cancer Medicine
|
October 13, 2020
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients
Andrew Belch, Nizar Bahlis, Darrell White, et al.
Leukemia & Lymphoma
|
February 26, 2008
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
Paul Richardson, Constantine Mitsiades, Kathleen Colson, et al.
Seminars in Oncology
|
April 30, 2003
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
Morie A Gertz, Athanasios Anagnostopoulos, Kenneth Anderson, et al.
Molecular Pharmacology
|
April 6, 2022
Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake
Vusumuzi N Hove, Kenneth Anderson, Elizabeth R Hayden, et al.
Page
of 11